These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 3092311)

  • 1. Safety and toxicity of a new serum immunoglobulin G intravenous preparation, IGIV pH 4.25.
    Pirofsky B
    Rev Infect Dis; 1986; 8 Suppl 4():S457-63. PubMed ID: 3092311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical use of a new pH 4.25 intravenous immunoglobulin preparation (gamimune-N).
    Pirofsky B
    J Infect; 1987 Jul; 15 Suppl 1():29-37. PubMed ID: 3117898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and patient acceptability of intravenous immune globulin in 10% maltose.
    Ochs HD; Buckley RH; Pirofsky B; Fischer SH; Rousell RH; Anderson CJ; Wedgwood RJ
    Lancet; 1980 Nov; 2(8205):1158-9. PubMed ID: 6107768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective and opsonic activities of a native, pH 4.25 intravenous immunoglobulin G preparation against common bacterial pathogens.
    Hill HR; Bathras JM
    Rev Infect Dis; 1986; 8 Suppl 4():S396-400. PubMed ID: 3092306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased incidence of adverse infusion reactions in hypogammaglobulinemic children receiving low pH intravenous immunoglobulin.
    Roberton DM; Hosking CS; Efthimiou H; Wright S; Upton H; Colgan T; Hartman L; Schiff P
    Aust N Z J Med; 1987 Oct; 17(5):495-500. PubMed ID: 3446162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three generations of immunoglobulin G preparations for clinical use.
    McCue JP; Hein RH; Tenold R
    Rev Infect Dis; 1986; 8 Suppl 4():S374-81. PubMed ID: 3092303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial.
    Roifman CM; Schroeder H; Berger M; Sorensen R; Ballow M; Buckley RH; Gewurz A; Korenblat P; Sussman G; Lemm G
    Int Immunopharmacol; 2003 Sep; 3(9):1325-33. PubMed ID: 12890430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of the biochemistry and safety of a new native intravenous gamma globulin, IGIV, pH 4.25.
    Schwartz RS
    Am J Med; 1987 Oct; 83(4A):46-51. PubMed ID: 3118708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune globulin subcutaneous, human - klhw 20% for primary humoral immunodeficiency: an open-label, Phase III study.
    Sleasman JW; Lumry WR; Hussain I; Wedner HJ; Harris JB; Courtney KL; Mondou E; Lin J; Stein MR
    Immunotherapy; 2019 Nov; 11(16):1371-1386. PubMed ID: 31621458
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease.
    Wasserman RL; Irani AM; Tracy J; Tsoukas C; Stark D; Levy R; Chen J; Sorrells S; Roberts R; Gupta S
    Clin Exp Immunol; 2010 Sep; 161(3):518-26. PubMed ID: 20550549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of a new, low-pH immunoglobulin G preparation during episodes of bacteremia in the rat.
    Emerson TE; Collins MS; Budinger MD
    Rev Infect Dis; 1986; 8 Suppl 4():S409-19. PubMed ID: 3092308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the clinical efficacy and safety of an intramuscular and an intravenous immunoglobulin preparation for replacement therapy in idiopathic adult onset panhypogammaglobulinaemia.
    Garbett ND; Currie DC; Cole PJ
    Clin Exp Immunol; 1989 Apr; 76(1):1-7. PubMed ID: 2500273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%).
    Ballow M; Berger M; Bonilla FA; Buckley RH; Cunningham-Rundles CH; Fireman P; Kaliner M; Ochs HD; Skoda-Smith S; Sweetser MT; Taki H; Lathia C
    Vox Sang; 2003 Apr; 84(3):202-10. PubMed ID: 12670369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Site of Care on Infection Rates Among Patients with Primary Immunodeficiency Diseases Receiving Intravenous Immunoglobulin Therapy.
    Wasserman RL; Ito D; Xiong Y; Ye X; Bonnet P; Li-McLeod J
    J Clin Immunol; 2017 Feb; 37(2):180-186. PubMed ID: 28160239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of immunoglobulins in pediatrics].
    Fischer A
    Arch Fr Pediatr; 1988 Dec; 45(10):779-81. PubMed ID: 3071284
    [No Abstract]   [Full Text] [Related]  

  • 16. Long term use of intravenous immune globulin in patients with primary immunodeficiency diseases: inadequacy of current dosage practices and approaches to the problem.
    Buckley RH
    J Clin Immunol; 1982 Apr; 2(2 Suppl):15S-21S. PubMed ID: 6806314
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of a new chemically modified intravenous IgG preparation in severe primary humoral immunodeficiency: clinical efficacy and attempts to individualize dosage.
    Schiff RI; Rudd C; Johnson R; Buckley RH
    Clin Immunol Immunopathol; 1984 Apr; 31(1):13-23. PubMed ID: 6421523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Half-life and clearance of pH 6.8 and pH 4.25 immunoglobulin G intravenous preparations in patients with primary disorders of humoral immunity.
    Schiff RI
    Rev Infect Dis; 1986; 8 Suppl 4():S449-56. PubMed ID: 3092310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1040 prophylactic infusions with an unmodified intravenous immunoglobulin product causing few side-effects in patients with antibody deficiency syndromes.
    Björkander J; Wadsworth C; Hanson LA
    Infection; 1985; 13(3):102-10. PubMed ID: 4030106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease.
    Heimall J; Chen J; Church JA; Griffin R; Melamed I; Kleiner GI
    J Clin Immunol; 2016 Aug; 36(6):600-9. PubMed ID: 27342758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.